Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
Subscribe To Our Newsletter & Stay Updated
